107.519 articles found

Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG.

Otsuka M, Kuwabara Y, Ichiya Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Kato M, Masuda K.

Ann Nucl Med · 1997-08-01

DOI: 10.1007/bf03164771PMID: 9310175

Use of propofol in patients with Parkinson's disease: report of a case.

Dewey CC.

CRNA · 1997-08-01

PMID: 9313435

The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II.

van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS.

Schizophr Res · 1997-08-01

DOI: 10.1016/s0920-9964(97)00058-3PMID: 9323356

Characteristics of the electromyographic patterns of lower limb muscles during gait in patients with Parkinson's disease when OFF and ON L-Dopa treatment.

Cioni M, Richards CL, Malouin F, Bedard PJ, Lemieux R.

Ital J Neurol Sci · 1997-08-01

DOI: 10.1007/bf02080464PMID: 9323513

[Electroconvulsive therapy in Parkinson disease. Description of three cases].

Avila A, Sastre F, Cardona X, Maho P, Bello J, Sancho I.

Neurologia · 1997-08-01

PMID: 9432202

The accelerated aging hypothesis of Parkinson's disease is not supported by the pattern of circadian melatonin secretion.

Sandyk R.

Int J Neurosci · 1997-08-01

DOI: 10.3109/00207459709000643PMID: 9352432

[Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].

Kuhn W, Müller T.

Fortschr Neurol Psychiatr · 1997-08-01

DOI: 10.1055/s-2007-996341PMID: 9378449

[Therapy of Parkinson disease. 2: New therapy concepts for treating motor symptoms].

Kuhn W, Müller T.

Fortschr Neurol Psychiatr · 1997-08-01

DOI: 10.1055/s-2007-996342PMID: 9378450

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE.

Brain Res · 1997-08-01

DOI: 10.1016/s0006-8993(97)00531-3PMID: 9359593

Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?

Krzaścik P, Kostowski W.

Pol J Pharmacol · 1997-08-01

PMID: 9437770

Parkinson's disease tests

MAYEUX RICHARD, GRAZIANO JOSEPH, FREYER GREG.

· 1997-07-03

The neuroregulatory properties of L-DOPA. A review of the evidence and potential role in the treatment of Parkinson's disease.

Tedroff JM.

Rev Neurosci · 1997-07-01

DOI: 10.1515/revneuro.1997.8.3-4.195PMID: 9548232